The Impact of Body Mass Index on Freedom From Therapeutic Intervention and Quality of Life in Active Surveillance Prostate Cancer Patients
Autor: | Gregory S. Merrick, Abbey Bennett, Brian S. Kurko, Robert W. Galbreath, Edward Adamovich, Wayne M. Butler, Ryan Fiano, Whitney Scholl |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
Cancer Research medicine.medical_specialty Urology Body Mass Index Prostate cancer Quality of life Erectile Dysfunction Biopsy medicine Humans Watchful Waiting Aged medicine.diagnostic_test business.industry Depression Prostatic Neoplasms Rectal examination Middle Aged Prostate-Specific Antigen medicine.disease Survival Rate Prostate-specific antigen Erectile dysfunction Oncology Quality of Life Sexual function business Body mass index Follow-Up Studies |
Zdroj: | American journal of clinical oncology. 44(8) |
ISSN: | 1537-453X |
Popis: | OBJECTIVE The objective of this study was to evaluate the impact of body mass index (BMI) on overall survival, freedom from distant metastases, rates of therapeutic intervention (TI), and quality of life (QOL) in active surveillance (AS) prostate cancer patients. MATERIALS AND METHODS Three hundred forty consecutive, prospectively evaluated AS patients underwent a staging transperineal template-guided mapping biopsy before AS enrollment and were stratified by BMI ( 35 kg/m2). Evaluated outcomes included overall survival, freedom from distant metastases, TI, QOL to include urinary, bowel, sexual function and depression and serial postvoid residual urine measurements. The relationship between BMI and anterior prostate cancer distribution was evaluated. Repeat biopsy was based on prostate specific antigen kinetics, abnormal digital rectal examination and patient preference. RESULTS Of the 340 patients, 323 (95%) were Gleason 3+3 and 17 patients (5.0%) were Gleason 3+4. The median follow-up was 5.2 years (range: 1 to 14 y). At 10 years, TI was instituted in 4.7%, 2.2%, 9.5%, and 25.0% of patients in BMI cohorts |
Databáze: | OpenAIRE |
Externí odkaz: |